Test Catalog

Test Id : PDETS

Not Orderable

Phosphodiesterase 10A (PDE10A) IgG, Tissue Immunofluorescence Titer, Serum

Download
Overview

Test Catalog

Useful For
Suggests clinical disorders or settings where the test may be helpful

Reporting an end titer result from phosphodiesterase 10A (PDE10A) in serum specimens

 

Evaluation of autoimmune/paraneoplastic neurological syndromes among patients presenting with movement disorders and encephalopathy

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

If the indirect immunofluorescence (IFA) pattern suggests phosphodiesterase 10A (PDE10A) IgG, then the PDE10A antibody IFA titer will be performed at an additional charge.

Method Name
A short description of the method used to perform the test

Only orderable as a reflex. For more information see:

ENS2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum

DMS2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Serum

EPS2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum

MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum

 

Indirect Immunofluorescence Assay (IFA)

NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test

PDE10A Ab IFA Titer, S

Aliases
Lists additional common names for a test, as an aid in searching

PDE10A

Phosphodiesterase 10A

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

If the indirect immunofluorescence (IFA) pattern suggests phosphodiesterase 10A (PDE10A) IgG, then the PDE10A antibody IFA titer will be performed at an additional charge.

Specimen Type
Describes the specimen type validated for testing

Serum

Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing

Only orderable as a reflex. For more information see:

ENS2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum

DMS2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Serum

EPS2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum

MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum

Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected

Gross hemolysis Reject
Thawing** Cold OK; Warm OK
Gross lipemia Reject
Gross icterus Reject

Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 28 days
Frozen 28 days
Ambient 72 hours

Useful For
Suggests clinical disorders or settings where the test may be helpful

Reporting an end titer result from phosphodiesterase 10A (PDE10A) in serum specimens

 

Evaluation of autoimmune/paraneoplastic neurological syndromes among patients presenting with movement disorders and encephalopathy

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

If the indirect immunofluorescence (IFA) pattern suggests phosphodiesterase 10A (PDE10A) IgG, then the PDE10A antibody IFA titer will be performed at an additional charge.

Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Phosphodiesterase 10A (PDE10A) is a marker of paraneoplastic neurological autoimmunity in patients presenting with movement disorders, encephalopathy and often cancer.

Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

Only orderable as a reflex. For more information see:

ENS2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum

DMS2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Serum

EPS2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum

MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum

 

<1:240

Interpretation
Provides information to assist in interpretation of the test results

A positive result is consistent with phosphodiesterase 10A (PDE10A) autoimmunity that manifests with autoimmune movement disorders or encephalitis. A paraneoplastic cause should be considered.

Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

A negative result does not exclude the presence of neurological autoimmunity or cancer. The use of immunosuppressive therapy prior to sample collection may negatively impact the sensitivity of this assay.

Clinical Reference
Recommendations for in-depth reading of a clinical nature

Zekeridou A, Kryzer T, Guo Y, et al. Phosphodiesterase 10A IgG: a novel biomarker of paraneoplastic neurologic autoimmunity. Neurology. 2019; 93(8):e815-e822. doi:10.1212/WNL.0000000000007971

Method Description
Describes how the test is performed and provides a method-specific reference

The patient's sample is tested by a standardized immunofluorescence assay that uses a composite frozen section of mouse cerebellum, kidney, and gut tissues. After incubation with sample and washing, fluorescein-conjugated goat-antihuman IgG is applied. Neuron-specific autoantibodies are identified by their characteristic fluorescence staining patterns. Samples that are scored positive for any neuronal nuclear or cytoplasmic autoantibody are titrated to an endpoint. Interference by coexisting non-neuron-specific autoantibodies can usually be eliminated by serologic absorption.(Honorat JA, Komorowski L, Josephs KA, et al. IgLON5 antibody: Neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm. 2017;4(5):e385. doi:10.1212/NXI.0000000000000385)

PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information

No

Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.

Monday through Sunday

Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.

5 to 10 days

Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

28 days

Performing Laboratory Location
Indicates the location of the laboratory that performs the test

Rochester

Fees
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.

  • Authorized users can sign in to Test Prices for detailed fee information.
  • Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
  • Prospective clients should contact their account representative. For assistance, contact Customer Service.

Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

CPT codes are provided by the performing laboratory.

86256

LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.

Test Id Test Order Name Order LOINC Value
PDETS PDE10A Ab IFA Titer, S 105523-5
Result Id Test Result Name Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
620070 PDE10A Ab IFA Titer, S 105523-5

Test Setup Resources

Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.

Excel | Pdf

Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.

Normal Reports | Abnormal Reports

SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.

SI Normal Reports | SI Abnormal Reports